Table 1.
Genotype frequencies of polymorphisms in NOD1, NOD2, TLR2, TLR4 and TLR9 and endometrial cancer risk
| Polymorphism | Genotypes | Cases n (%) | Controls n (%) | χ2 | OR (95% CI) and p value |
|---|---|---|---|---|---|
| TT | 119 (62.3) | 176 (60.5) | |||
| NOD1 (rs2075822) | TC | 62 (32.5) | 105 (36.1) | 1.188 | |
| CC | 10 (5.2) | 10 (3.4) | p = 0.497 | (0.774-1.823) p = 0.432 | |
| TC+CC | 72 (37.7) | 115 (39.5) | |||
| AA | 104 (54.5) | 152 (52.2) | |||
| NOD1 (rs2907749) | AG | 68 (35.6) | 118 (40.6) | 1.156 | |
| GG | 19 (9.9) | 21 (7.2) | p = 0.392 | (0.759-1.761) p = 0.499 | |
| AG+GG | 87 (45.5) | 139 (47.8) | |||
| CC | 114 (59.7) | 168 (57.7) | |||
| NOD1 (rs2907748) | CT | 64 (33.5) | 110 (37.8) | 1.156 | |
| TT | 13 (6.8) | 13 (4.5) | p = 0.400 | (0.755-1.769) p = 0.505 | |
| CT+TT | 77 (40.3) | 123 (42.3) | |||
| CC | 182 (95.3) | 282 (96.9) | 1.549 | ||
| NOD2 (rs5743260) | CT | 9 (4.7) | 9 (3.1) | p = 0.359 | (0.604-3.977) p = 0.363 |
| TT | 0 (0.0) | 0 (0.0) | |||
| CC | 178 (93.2) | 263 (90.4) | 0.928 | ||
| NOD2 (rs2066844) | CT | 13 (6.8) | 28 (9.6) | p = 0.278 | (0.407-2.116) p = 0.859 |
| TT | 0 (0.0) | 0 (0.0) | |||
| GG | 187 (97.9) | 282 (96.9) | 0.636 | ||
| NOD2 (rs2066845) | GC | 4 (2.1) | 9 (3.1) | p = 0.508 | (0.143-2.835) p = 0.553 |
| CC | 0 (0.0) | 0 (0.0) | |||
| GG | 177 (92.7) | 275 (94.5) | 1.190 | ||
| TLR2 (rs5743708) | GA | 14 (7.3) | 16 (5.5) | p = 0.416 | (0.501-2.826) p = 0.694 |
| AA | 0 (0.0) | 0 (0.0) | |||
| AA | 163 (85.3) | 258 (88.7) | |||
| TLR4 (rs4986790) | AG | 25 (13.1) | 31 (10.6) | 1.098 | |
| GG | 3 (1.6) | 2 (0.7) | p = 0.449 | (0.573-2.101) p = 0.778 | |
| AG+GG | 28 (14.7) | 33 (11.3) | |||
| TT | 85 (44.5) | 116 (39.9) | |||
| TLR9 (rs5743836) | TC | 79 (41.4) | 128 (44.0) | 0.781 | |
| CC | 27 (14.1) | 47 (16.1) | p = 0.581 | (0.511-1.195) p = 0.255 | |
| TC+CC | 106 (55.5) | 175 (60.1) | |||
| TT | 138 (72.25) | 187 (64.3) | |||
| TLR9 (rs187084) | TC | 49 (25.65) | 88 (30.2) | 0.675 | |
| CC | 4 (2.1) | 16 (5.5) | p = 0.076 | (0.428-1.064) p = 0.091 | |
| TC+CC | 53 (27.75) | 104 (35.7) |
NB: Χ2 - Wild-type genotype versus heterozygous genotype versus homozygous variant genotype. Odds ratios for polymorphisms in NOD1, TLR4 and TLR9 were calculated as follows: Wild Type genotype compared to combination of heterozygous and homozygous variant genotypes. Odds ratios for polymorphisms in NOD2 and TLR2 were calculated as follows: Wild Type genotype compared to heterozygous genotype. All Odds Ratios were adjusted for age, BMI, diabetes, HBP, history of cancer, HT, smoking and alcohol use.